A 2.5-Year Within-Patient Evolution of Pseudomonas aeruginosa Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment | Zendy

Thibaud Boulant | Zendy; Agnès B. Jousset | Zendy; Rémy A. Bonnin | Zendy; Aurélie BarrailTran | Zendy; Adrien Borgel | Zendy; Saoussen Oueslati | Zendy; Thierry Naas | Zendy; Laurent Dortet | Zendy

Open Access

A 2.5-Year Within-Patient Evolution of Pseudomonas aeruginosa Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment

Author(s) -

Thibaud Boulant,

Agnès B. Jousset,

Rémy A. Bonnin,

Aurélie BarrailTran,

Adrien Borgel,

Saoussen Oueslati,

Thierry Naas,

Laurent Dortet

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01637-19

Subject(s) - tazobactam , ceftazidime/avibactam , ceftazidime , pseudomonas aeruginosa , piperacillin/tazobactam , microbiology and biotechnology , meropenem , piperacillin , medicine , imipenem , biology , antibiotic resistance , antibiotics , bacteria , genetics

Ceftolozane-tazobactam is considered to be a last-resort treatment for infections caused by multidrug-resistant (MDR)Pseudomonas aeruginosa . Although resistance to this antimicrobial has been describedin vitro , the development of resistancein vivo has rarely been reported. Here, we describe the evolution of resistance to ceftolozane-tazobactam ofP. aeruginosa isolates recovered from the same patient during recurrent infections over 2.5 years.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research